94 related articles for article (PubMed ID: 17105913)
1. Age-dependent effects of methamphetamine on VMAT-2.
Rau KS; Truong JG; Wilkins DG; Fleckenstein AE; Hanson GR
Ann N Y Acad Sci; 2006 Aug; 1074():154-9. PubMed ID: 17105913
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
3. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
5. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
Volz TJ; Hanson GR; Fleckenstein AE
Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
[TBL] [Abstract][Full Text] [Related]
7. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
Hanson GR; Sandoval V; Riddle E; Fleckenstein AE
Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
9. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
Bjorklund NL; Sorg BA; Schenk JO
Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
[TBL] [Abstract][Full Text] [Related]
10. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.
Johnson-Davis KL; Truong JG; Fleckenstein AE; Wilkins DG
J Pharmacol Exp Ther; 2004 May; 309(2):578-86. PubMed ID: 14747615
[TBL] [Abstract][Full Text] [Related]
11. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2006 Jul; 155(1):109-15. PubMed ID: 16480775
[TBL] [Abstract][Full Text] [Related]
12. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice.
Ji J; McDermott JL; Dluzen DE
J Neuroendocrinol; 2007 Sep; 19(9):725-31. PubMed ID: 17680888
[TBL] [Abstract][Full Text] [Related]
14. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
15. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
Rau KS; Birdsall E; Volz TJ; Riordan JA; Baucum AJ; Adair BP; Bitter R; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
[TBL] [Abstract][Full Text] [Related]
17. [New perspectives on the mechanism of methamphetamine-induced neurotoxicity].
Kita T; Takeshima M; Wagner GC; Hozumi H; Miyazaki I; Asanuma M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):49-61. PubMed ID: 18516983
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death.
Kanthasamy A; Anantharam V; Ali SF; Kanthasamy AG
Ann N Y Acad Sci; 2006 Aug; 1074():234-44. PubMed ID: 17105920
[TBL] [Abstract][Full Text] [Related]
19. Vesicular monoamine transporter 1 mediates dopamine secretion in rat proximal tubular cells.
Maurel A; Spreux-Varoquaux O; Amenta F; Tayebati SK; Tomassoni D; Seguelas MH; Parini A; Pizzinat N
Am J Physiol Renal Physiol; 2007 May; 292(5):F1592-8. PubMed ID: 17244889
[TBL] [Abstract][Full Text] [Related]
20. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
